Business Context and Reporting Period
This Form 8-K is filed by TransBiotec, Inc. (not SOBR Safe, Inc.) for the reporting period ending September 14, 2016. The filing addresses corporate governance changes under Item 5.02, specifically the appointment of a new Chief Financial Officer and the resignation of a Board member.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and contains no financial performance data.
Material Changes
- Appointment of CFO: On September 14, 2016, the Board appointed John O'Brien as Chief Financial Officer. Mr. O'Brien brings extensive experience from Bank of America (2005-2010) and MBNA America Bank (1990-2005), including managing expense plans and revenue forecasts for credit card operations.
- Board Resignation: On October 12, 2016, Ronald Williams resigned from the Board of Directors. The company states there were no disagreements requiring disclosure.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies related to the company's operations are disclosed in this document, other than the standard procedural note regarding the opportunity for the resigning director to provide a dissenting letter.
Investor Verification Checklist
- Verify the correct registrant name is TransBiotec, Inc. (the input metadata listed "SOBR Safe, Inc." which appears to be an error).
- Confirm the effective date of John O'Brien's tenure as CFO (September 14, 2016).
- Check for any subsequent filings regarding a dissenting letter from the resigned director, Ronald Williams.
- Review the company's most recent 10-K or 10-Q for actual financial metrics, as this 8-K contains none.